Dupilumab During Pregnancy: What a 293-Patient Cohort Can—and Cannot—Reassure About

Planning a pregnancy or discovering one during eczema treatment can raise an urgent question: what should happen to the next prescription dose? Dupilumab decisions need the prescribing clinician and pregnancy-care team. A reassuring observational study can inform that conversation without becoming an instruction to continue, stop or change treatment on your own.

What was compared in the 2025 study?

A propensity-matched electronic-record cohort compared 293 pregnant women exposed to dupilumab with an equally sized group without exposure. Participants had type 2 inflammatory diseases, including eczema, asthma and other conditions. This was not a randomized eczema-only pregnancy trial.

The study found no increased risk in its measured maternal adverse pregnancy outcomes. The composite 'any adverse pregnancy outcome' had a hazard ratio of 0.53 (95% confidence interval 0.33–0.84). That association does not show that dupilumab prevents pregnancy complications: matching cannot remove every difference between treated and untreated groups.

Crucially, the researchers analyzed maternal diagnoses, without fetal records because of privacy protocols. They could not determine administration frequency, discontinuation patterns or comparable disease severity. Exposure meant at least one dose; it does not necessarily mean treatment throughout pregnancy. These boundaries prevent extending the result to all fetal outcomes or every exposure schedule.

What does the current label say?

The current U.S. dupilumab label reports that available case reports and case series have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. That wording describes the available evidence; it does not guarantee absence of risk. The label also identifies a pregnancy exposure registry.

IgG antibodies cross the placenta, with transport increasing as pregnancy progresses. The label therefore says potential effects in infants exposed in utero should be considered. Pregnancy timing and treatment history belong in the discussion. The same label treats breastfeeding as a separate question, noting absent data on human milk, milk production and effects on breastfed infants.

Keep a treatment plan while uncertainty is addressed

NIAMS describes individualized eczema treatment based on the rash, response and person's circumstances, with regular follow-up. Tell the team if itch, sleep loss or difficulties obtaining treatment are affecting daily life. Those details should remain part of the decision alongside the pregnancy evidence.

Our pregnancy care guide starts the broader conversation. The topical-steroid birth-weight study concerns different exposures and outcomes; its findings cannot be transferred to dupilumab. Our dupilumab introduction covers efficacy research outside this pregnancy cohort.

Ask for a coordinated answer you can follow

Ask who will document the decision, when it will be revisited and whom to contact before a scheduled dose if the plan is unclear. If different teams give conflicting advice, ask them to coordinate. A written list of dose dates and questions can make a short appointment more useful.

Discuss product suitability separately, including the current moisturizer ingredient list. None of the pregnancy findings discussed here establish pregnancy safety for #003. This article's product illustration shows an adult activity setting and is not a pregnancy outcome or treatment result.

Other dupilumab safety questions require their own evidence. Our eosinophil blood-count guide addresses a separate outcome; its mixed-disease analysis does not answer pregnancy questions.